Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case

World Journal of Surgical Oncology

Volumn 4, Issue , 2006, Pages

  Braumann, Chris ^a   Winkler, Goetz L ^a   Rogalla, Patrick ^a   Menenakos, Charalambos ^a   Jacobi, Christoph A ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TAUROLIDINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; ESOPHAGOJEJUNOSTOMY; FATALITY; HEART INFARCTION; HEPATIC ARTERY; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LIVER RESECTION; MALE; NEPHRECTOMY; PARTIAL GASTRECTOMY; POSTOPERATIVE PERIOD; RADIOFREQUENCY ABLATION; REOPERATION; STOMACH ADENOCARCINOMA; TREATMENT OUTCOME; UROGENITAL TRACT TUMOR;

EID: 33747603201     PISSN: 14777819     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-4-34     Document Type: Article

References (26)

1. Maeta M, Yamashiro H, Saito H, Katano K, Kondo A, Tsujitani S, Ikeguchi M, Kaibara N: A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery 1999, 125:325-331.
2. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996, 347:995-999.
3. Wanebo HJ, Kennedy BJ, Winchester DP, Fremgen A, Stewart AK: Gastric carcinoma: does lymph node dissection alter survival? J Am Coll Surg 1996, 183:616-624.
4. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, van Elk P, Obertop H, Gouma DJ, Taat CW,.: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995, 345:745-748.
5. Klein HO: [Neo-adjuvants, adjuvants and palliative therapy for gastric carcinoma]. Schweiz Rundsch Med Prax 1998, 87:451-454.
6. Jacobi CA, Peter FJ, Wenger FA, Ordemann J, Muller JM: New therapeutic strategies to avoid intra- and extraperitoneal metastases during laparoscopy: results of a tumor model in the rat. Dig Surg 1999, 16:393-399.
7. McCourt M, Wang JH, Sookhai S, Redmond HP: Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 2000, 7:685-691.
8. Braumann C, Ordemann J, Wildbrett P, Jacobi CA: Influence of intraperitoneal and systemic application of taurolidine and taurolidine/ heparin during laparoscopy on intraperitoneal and subcutaneous tumour growth in rats. Clin Exp Metastasis 2000, 18:547-552.
9. Braumann C, Ordemann J, Kilian M, Wenger FA, Jacobi CA: Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy. Clin Exp Metastasis 2003, 20:387-394.
10. Calabresi P, Goulette FA, Darnowski JW: Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 2001, 61:6816-6821.
11. Han Z, Ribbizi I, Pantazis P, Wyche J, Darnowski J, Calabresi P: The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Anticancer Res 2002, 22:1959-1964.
12. Shrayer DP, Lukoff H, King T, Calabresi P: The effect of Taurolidine on adherent and floating subpopulations of melanoma cells. Anticancer Drugs 2003, 14:295-303.
13. Stendel R, Stoltenburg-Didinger G, Al Keikh CL, Wattrodt M, Brock M: The effect of taurolidine on brain tumor cells. Anticancer Res 2002, 22:809-814.
14. Van Antwerp DJ, Martin SJ, Verma IM, Green DR: Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell Biol 1998, 8:107-111.
15. Braumann C, Henke W, Jacobi CA, Dubiel W: The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. Int J Cancer 2004, 112:225-230.
16. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC,.: The European Organization for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
17. de Manzoni G, Verlato G, Guglielmi A, Laterza E, Genna M, Cordiano C: Prognostic significance of lymph node dissection in gastric cancer. Br J Surg 1996, 83:1604-1607.
18. Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P, Meyer HJ: Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg 1993, 80:1015-1018.
19. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Van de Velde CJ: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993, 11:1441-1447.
20. Nakajima T: Review of adjuvant chemotherapy for gastric cancer. World J Surg 1995, 19:570-574.
21. Darnowski JW, Goulette FA, Cousens LP, Chatterjee D, Calabresi P: Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol 2004, 54:249-258.
22. Nici L, Monfils B, Calabresi P: The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res 2004, 10:7655-7661.
23. Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W, Brock M: Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res 2004, 24:1143-1147.
24. Yanagisawa M, Imai H, Fukushima Y, Yasuda T, Miura AB, Nakamoto Y: Effects of tumour necrosis factor alpha and interleukin I beta on the proliferation of cultured glomerular epithelial cells. Virchows Arch 1994, 424:581-586.
25. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, Nakayama J, Nishioka Y, Sone S, Kuwano M: Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer 2000, 85:182-188.
26. Ribizzi I, Darnowski JW, Goulette FA, Akhtar MS, Chatterjee D, Calabresi P: Taurolidine: preclinical evaluation of a novel, highly selective, agent for bone marrow purging. Bone Marrow Transplant 2002, 29:313-319.